Annexin Pharmaceuticals AB (ANNX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.380x

Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has a cash flow conversion efficiency ratio of -0.380x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-9.48 Million ≈ $-1.02 Million USD) by net assets (Skr24.93 Million ≈ $2.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Annexin Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Annexin Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ANNX total liabilities for a breakdown of total debt and financial obligations.

Annexin Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Annexin Pharmaceuticals AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Delixy Holdings Limited Ordinary Shares NASDAQ:DLXY	N/A
Energoinstal S.A. WAR:ENI	0.031x
Dycasa SA BA:DYCA	-0.135x
eEducation Albert AB ST:ALBERT	-0.185x
Max Resource Corp V:MAX	-0.139x
Sirona Biochem Corp V:SBM	0.160x
Biovie Inc NASDAQ:BIVI	-0.230x
Calibre PA:ALWIN	0.411x

Annual Cash Flow Conversion Efficiency for Annexin Pharmaceuticals AB (2015–2025)

The table below shows the annual cash flow conversion efficiency of Annexin Pharmaceuticals AB from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Annexin Pharmaceuticals AB market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr24.93 Million ≈ $2.68 Million	Skr-36.92 Million ≈ $-3.97 Million	-1.481x	+59.57%
2024-12-31	Skr13.71 Million ≈ $1.48 Million	Skr-50.23 Million ≈ $-5.41 Million	-3.663x	-58.77%
2023-12-31	Skr18.81 Million ≈ $2.02 Million	Skr-43.40 Million ≈ $-4.67 Million	-2.307x	-68.98%
2022-12-31	Skr30.15 Million ≈ $3.24 Million	Skr-41.16 Million ≈ $-4.43 Million	-1.365x	-41.68%
2021-12-31	Skr46.73 Million ≈ $5.03 Million	Skr-45.02 Million ≈ $-4.85 Million	-0.964x	+49.27%
2020-12-31	Skr20.64 Million ≈ $2.22 Million	Skr-39.20 Million ≈ $-4.22 Million	-1.899x	+15.17%
2019-12-31	Skr11.49 Million ≈ $1.24 Million	Skr-25.73 Million ≈ $-2.77 Million	-2.239x	-213.04%
2018-12-31	Skr39.85 Million ≈ $4.29 Million	Skr-28.50 Million ≈ $-3.07 Million	-0.715x	+55.27%
2017-12-31	Skr24.44 Million ≈ $2.63 Million	Skr-39.08 Million ≈ $-4.21 Million	-1.599x	-150.32%
2016-12-31	Skr15.57 Million ≈ $1.68 Million	Skr-9.95 Million ≈ $-1.07 Million	-0.639x	-101.75%
2015-12-31	Skr-137.00K ≈ $-14.74K	Skr-5.01 Million ≈ $-539.37K	36.584x	--

About Annexin Pharmaceuticals AB

ST:ANNX Sweden Biotechnology

Market Cap

$11.24 Million

Skr104.47 Million SEK

Market Cap Rank

#26581 Global

#577 in Sweden

Share Price

Skr14.80

Change (1 day)

-1.33%

52-Week Range

Skr0.27 - Skr37.00

All Time High

Skr37.00